Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Bristol-Myers Squibb
Bristol-Myers Squibb
Yale University
BicycleTx Limited
Nanobiotix
Maastricht University Medical Center
University of Kansas Medical Center
Memgen, Inc.
Incyte Corporation
Bristol-Myers Squibb
Washington University School of Medicine
Exelixis
Compugen Ltd
Georgetown University
Centre Leon Berard
Jonsson Comprehensive Cancer Center
Tempest Therapeutics
Nektar Therapeutics
Nektar Therapeutics
Calithera Biosciences, Inc
Incyte Corporation
Duke University
Infinity Pharmaceuticals, Inc.
Odonate Therapeutics, Inc.
Sheba Medical Center
MultiVir, Inc.
Celgene
National Cancer Institute (NCI)